Thrivent Financial for Lutherans Has $41.44 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Thrivent Financial for Lutherans decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,231 shares of the company’s stock after selling 8,027 shares during the period. Thrivent Financial for Lutherans owned 0.12% of IDEXX Laboratories worth $41,439,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in IDXX. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on IDXX shares. Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, March 15th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Stock Up 0.6 %

IDEXX Laboratories stock opened at $422.15 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm’s 50-day simple moving average is $437.54 and its 200 day simple moving average is $445.70. The stock has a market cap of $34.33 billion, a PE ratio of 39.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.